BBTX · Bambusa Therapeutics, Inc. · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↓
Filing footnotes — Series Seed Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by MiNeng, Inc. ("MiNeng"). The Reporting Person is the President and sole stockholder of MiNeng and therefore has sole voting and dispositive power with regard to the shares held by MiNeng. |
Series Seed Preferred Stock
(I)
|
94,050 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Nexus Fund III. |
Series A-2 Preferred Stock
(I)
|
52,932 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Other↓
Filing footnotes — Series A-1 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Nexus Fund III. |
Series A-1 Preferred Stock
(I)
|
1,278,148 |
| 2026-11-02 | Jeggle Helmut Wolfgang |
Director |
Other↓
Filing footnotes — Series Seed Plus Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. |
Series Seed Plus Preferred Stock
(I)
|
3,135,066 |
| 2026-11-02 | Jeggle Helmut Wolfgang |
Director |
Other↓
Filing footnotes — Series A-1 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. |
Series A-1 Preferred Stock
(I)
|
1,473,775 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Nexus Fund III. |
Common Stock
(I)
|
164,891 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. |
Series A-2 Preferred Stock
(I)
|
299,948 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Other↓
Filing footnotes — Series A-1 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. |
Series A-1 Preferred Stock
(I)
|
2,844,910 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Nexus Fund III. |
Common Stock
(I)
|
1,331,080 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↓
Filing footnotes — Series Seed Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
Series Seed Preferred Stock
(I)
|
10,450 |
| 2026-11-02 | Salvia Investment GmbH |
10% Owner |
Other↓
Filing footnotes — Series A-1 Preferred Stock (Direct)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
Series A-1 Preferred Stock
|
1,473,775 |
| 2026-11-02 | Jeggle Helmut Wolfgang |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. |
Common Stock
(I)
|
375,000 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by The Shanshan Xu 2025 Irrevocable Family Trust ("Xu Trust"). The Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by the Xu Trust. |
Common Stock
(I)
|
16,358 |
| 2026-11-02 | Jeggle Helmut Wolfgang |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. |
Common Stock
(I)
|
4,769,701 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by MiNeng, Inc. ("MiNeng"). The Reporting Person is the President and sole stockholder of MiNeng and therefore has sole voting and dispositive power with regard to the shares held by MiNeng. |
Common Stock
(I)
|
147,238 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. |
Common Stock
(I)
|
2,335,109 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↓
Filing footnotes — Series Seed Plus Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by MiNeng, Inc. ("MiNeng"). The Reporting Person is the President and sole stockholder of MiNeng and therefore has sole voting and dispositive power with regard to the shares held by MiNeng. |
Series Seed Plus Preferred Stock
(I)
|
37,399 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↓
Filing footnotes — Series A-1 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by The Shanshan Xu 2025 Irrevocable Family Trust ("Xu Trust"). The Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by the Xu Trust. |
Series A-1 Preferred Stock
(I)
|
1,753 |
| 2026-11-02 | Salvia Investment GmbH |
10% Owner |
Other↓
Filing footnotes — Series Seed Plus Preferred Stock (Direct)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
Series Seed Plus Preferred Stock
|
3,135,066 |
| 2026-11-02 | Salvia Investment GmbH |
10% Owner |
Other↑
Filing footnotes — Common Stock (Direct)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
Common Stock
|
4,769,701 |
| 2026-11-02 | Salvia Investment GmbH |
10% Owner |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Direct)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
Series A-2 Preferred Stock
|
160,860 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↓
Filing footnotes — Series Seed Plus Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by The Shanshan Xu 2025 Irrevocable Family Trust ("Xu Trust"). The Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by the Xu Trust. |
Series Seed Plus Preferred Stock
(I)
|
4,155 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. |
Common Stock
(I)
|
3,144,858 |
| 2026-11-02 | Jeggle Helmut Wolfgang |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. |
Series A-2 Preferred Stock
(I)
|
160,860 |
| 2026-11-02 | Xu Shanshan |
Director, See remarks, 10% Owner |
Other↓
Filing footnotes — Series A-1 Preferred Stock (Indirect)
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Shares held by MiNeng, Inc. ("MiNeng"). The Reporting Person is the President and sole stockholder of MiNeng and therefore has sole voting and dispositive power with regard to the shares held by MiNeng. |
Series A-1 Preferred Stock
(I)
|
15,789 |
| 2026-11-02 | Salvia Investment GmbH |
10% Owner |
Buy↑
|
Common Stock
|
375,000 |
| 2026-10-30 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. |
Common Stock
(I)
|
189,909 |
| 2026-10-30 | RA CAPITAL MANAGEMENT, L.P. |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. |
Common Stock
(I)
|
263,911 |
| 2026-10-29 | Xu Shanshan |
Director, See remarks, 10% Owner |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest upon the Administrator (as defined in the Issuer's 2026 Equity Incentive Plan) determining and certifying the achievement of the weighted average price of a share of the Issuer's common stock equals or exceeds $32 for any period of 30 consecutive trading days following April 1, 2027 and prior to April 1, 2030. |
Restricted Stock Units
|
758,204 |
| 2026-10-29 | Xu Shanshan |
Director, See remarks, 10% Owner |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 29, 2026. |
Stock Option (right to buy)
|
379,102 |